FOGHORN THERAPEUTICS INC. (FHTX) - FOGHORN THERAPEUTICS INC

Explicit Guidance:

• Cash Runway: Funding extended through the second half of 2029, covering the End of Non-GLP Tox, IND for EP300, and INI clinical initiation, with approximately one year of cash remaining post-SADMAD for the INI program.
• Clinical Milestones (IN1/INI Program):
  • Start non-GLP tox studies (rat and dog, 2-week evaluation) in December (current year).
  • Target first-in-human (FIH) studies to commence before the end of 2027.
  • Goal to generate First-In-Patient (SADMAD) data by the second half of 2028 (Q3 timeframe).
• Clinical Milestones (EP300 Program): Target Investigational New Drug (IND) application submission by the end of 2027.
• Clinical Milestones (CBP Program): Decision point ("go/no-go") expected in the first half of 2025 following in vivo pharmacology to determine human dose projections.
• Data Release: Additional cytokine impact and safety data for the INI program expected in the first half of the upcoming year.
• Platform Validation: In vitro proof-of-concept for induced proximity chemistry and potential new data expected in the first half of next year.

Business-Segment Outlook:

• Oncology (EP300): Focused on hematological malignancies, specifically multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Program utilizes a once-a-week subcutaneous formulation with backup oral efforts. Seeks to avoid thrombocytopenia by selectively targeting EP300 over CBP, contrasting with dual inhibitors.
• Oncology (CBP): Targeting ER-positive breast cancer; currently delayed due to CRO animal facility loss, requiring re-execution of in vivo models and combination studies with CDK4-6/SIRDs.
• Immunology (INI): Focused on Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's); targeting a novel INI mechanism with no known public competitors. Early data in T-cell transfer and IL-10 knockout colitis models comparable to murine anti-IL-12/23 antibody. Also exploring activity in psoriasis.
• Platform Expansion: Shifting focus to "induced proximity" to degrade secreted protein cytokines and transmembrane proteins via the endoplasmic reticulum (ER). Targets include IL-12, IL-23, IL-17, TNF-alpha, PD-L1, and EGFR. Pipeline moving toward molecular glues.

Market and Competitive Outlook:

• Multiple Myeloma: Recognized as a chronic disease with expanding patient populations despite existing mechanisms (CD38, BCMA, IMiD, proteasome inhibitors). Opportunity identified for orthogonal mechanisms in later-line settings (2nd, 3rd, 4th line) and combination therapies.
• Target Validation: Dual CBP-EP300 inhibition (e.g., Cellcentric's program) validates the area, but Foghorn anticipates superior tolerability and efficacy through high selectivity (100-fold to 10,000-fold over CBP).
• Competitive Landscape: No known public competitors for the specific INI target in IBD.
• Strategic Positioning: Skepticism regarding the SMARCA2 target due to lack of clinical translation despite safe molecule; expects other industry programs on this target to face similar biological hurdles.

Macro / Industry Outlook:

• Biotech Sentiment: Acknowledges that "hope springs eternal" in the industry, but suggests capital allocation to SMARCA2 should be skeptical given current evidence.
• Capital Efficiency: Emphasizes the necessity of selective drug targeting to mitigate cytopenia risks when combining with other cytopenic therapies (e.g., anti-BCMA, pomalidomide).

Strategic Initiatives:

• Partnership Strategy: Open to strategic partnership for the EP300 program before clinical initiation, particularly for oncology indications requiring complex combination trials. Similarly open to partnerships for the induced proximity platform once chemical matter is validated.
• Restructuring: Recent restructuring (October) extended cash runway and re-aligned resources toward the new pipeline focus.
• Technology Evolution: Transitioned from BAF complex/synthetic lethality (FHD-909) to selective degradation/protein targeting (INI, EP300, CBP) and induced proximity biology.
• M&A/Divestment: No specific M&A mentioned; focus is on "life cycle management" and potential divestment/partnering of specific asset classes (EP300, induced proximity) to create value.

Risks and Headwinds to Outlook:

• Clinical Execution: Potential failure of IND filing timelines or clinical trial outcomes for EP300 and INI programs.
• Operational Delays: Past delay in the CBP program due to a CRO losing its animal facility; similar operational risks exist for in vivo model re-execution.
• Biological Uncertainty: Risk that the specific ER-based induced proximity mechanism or the high-selectivity thresholds (100x vs. 1000x) may not yield expected clinical efficacy.
• Market Dynamics: Potential for competitors to advance dual CBP-EP300 programs, though Foghorn expects selectivity advantages to persist.
• Timing Sensitivity: Missed deadlines on non-GLP tox or FIH studies could push the "2027" and "2028" targets out, potentially extending cash burn.

Management Tone on the Future:

• Cautiously Optimistic: Management expresses strong conviction in the platform's ability to target "challenging" proteins and the specific opportunity in IBD and myeloma.
• Pragmatic: Willing to pivot away from unproven biology (SMARCA2) and delay specific programs (CBP) to ensure data quality.
• Forward-Looking Confidence: High confidence in the INI program's unique positioning and the EP300 program's potential to solve tolerability issues.
• Transparency: Explicitly acknowledges past setbacks (FHD-909, CRO issues) while framing them as catalysts for strategic evolution rather than failures of execution.

Miscellaneous:

• Target Specifics: FHD-909 (SMARCA2) program discontinued after clinical data failed to translate preclinical excitement.
• Product Format: EP300 and CBP candidates designed as once-a-week long-acting injectables.
• Regulatory Path: INI program tracks toward Non-GLP (2-week rat/dog) followed by GLP toxicology to support FIH.
• Data Disclosure: Specific cytokine impact data and safety updates for INI to be released in the first half of next year; more data on the induced proximity platform expected in H1 next year.